Last Updated: 6/24/2009

Clinical Interests
Colorectal and other GI Cancers
Carcinoid and GI tract neuroendocrine tumors
New drug development
Inherited predisposition to GI cancers

Research Interests
My research is focused on four areas: 1.) clinical studies in patients with GI cancers (principally colorectal cancer); 2.) translational studies done on biologic specimens from patients with cancer done with laboratory collaborators; 3.) development of new cancer drugs and drug combinations; and, 4.) clinical trials methodology.

I am the Principal Investigator of national intergroup study N9741, an international Phase III study of oxaliplatin, irinotecan and 5-fluorouracil in combinations for first-line treatment of advanced colorectal cancer. New drug combinations are tested with the endpoints of time to progression, response rate, survival, toxicity and blood samples are examined for pharmacogenetic correlations to toxicity. This trial has been a major factor in changing the standard of practice for treatment of metastatic colorectal cancer in North America. It has also pioneered the field of pharmacogenetics in determining both treatment response and toxicity in colorectal cancer.
As Chair of the CALGB GI Committee I run a program that devises Phase II and III studies in GI cancers directed toward improving outcomes for GI cancer patients and understanding the biology of these diseases.

Recent Accomplishments and Honors
Listed in Best Doctors since 2001 and Who's Who in Medical Sciences Education
Recipient Mayo Clinic Individual Achievement Award 2003.
Chair, Gastrointestinal Cancer Committee For the cooperative onoclogy research group Cancer and Acute Leukemia Group B (CALGB)
Past President International Society of Gastrointestinal Oncology (ISGIO)

Training
Harvard University, BA, 1975, Biology, cum laude
Upstate Medical Center, Syracuse, NY, MD, 1979, Medicine

Publications
1. McWhinney S, Goldberg RM, McLeod HL. Platinum Neurotoxicity. Pharmacogenetics. Mol Canc Ther, 8:10-16,2009.
2. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollack M. Insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: Results from intergroup trial N9741. Clin Canc Res, 14:8263-69, 2008.
3. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. N9741: 5 Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer. J Clin Oncol, EPub ahead of print 11/11/08. 26:5721-5727, 2008.
4. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset J-F, Cunningham D, de Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang Y-K, Kerr D, Labianca R, Minsky B, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll H-J, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol. 19(Suppl 6):1-8, 2008.
5. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic Significance of Defective Mismatch Repair and BRAF-V600E in Patients with Colon Cancer. Clin Can Res, 14:3408-15, 2008.
6. Meropol NJ, Niedzwiecki D, Shank B, Colacchio TA, Ellerton J, Valone F, Budinger S, Day JM, Hopkins J, Tepper J, Goldberg RM, Mayer RJ. Induction Therapy for Poor-Prognosis Anal Canal Carcinoma: A Phase II Study of the Cancer and Leukemia Group B (CALGB 9281). J Clin Oncol. 2008 E pub May 19. 26: 3229-3234, 2008.
7. Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Impact of Family History on Cancer Recurrence and Survival among Patients with Stage III Colon Cancer: Findings from CALGB 89803. JAMA, 299:2515-2523, 2008.
8. Caudle AS, Kim HJ, Tepper JE, O'Neil BH, Lange LA, Goldberg RM, Bernard SA, Calvo BF, Meyers MO. Diabetes Mellitus Affects Response to Neoadjuvant Chemoradiotherapy in the Management of Rectal Cancer. Ann Surg Oncol. Epub 4/17/2008.
9. O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz J-F, Benedetti J, Andr T, Haller DG, and Sargent DJ, for the ACCENT Collaborative Group. Survival Following Recurrence in Stage II and III Colon Cancer: Findings from the ACCENT Dataset, J Clin Oncol, 10:2336-41, 2008.
10. Stinchcombe TE, Socinski MA, Lee CB, Hayes DN, Moore DT, Goldberg RM. Dees EC. A Phase I trial on nanoalbumen-bound paclitaxel (NAB-paclitaxel) in combination with gemcitabine in patients with thoractic malignancies. J Thor Oncol. 3:521-6, 2008.
11. Kohne C-H, Folprecht G, Goldberg RM, Rougier P. Irinotecan and other chemotherapy in elderly patients with colorectal cancer. The Oncologist, 13:390-402, 2008.
12. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086-92, 2008.
13. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ. Response-independent survival benefit in metastatic colorectal cancer: comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183-189, 2008.
14. Posner MC, Niedzwiecki DN, Venook AP, Hollis DR, Schilsky RL, Goldberg RM, Mayer RJ. A phase II prospective multi-institutional trial (CALGB 89903) of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases. Ann Surg, 15:158-164, 2008.
15. Yen-Rovollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res. 14:8-13, 2008.
16. Goldberg RM, Carrato A. Progress in 2007 in the current treatment of advanced colorectal cancer. Gast Can Res. 2:S1, S19-24, 2008.
17.Shah U*, Goldberg RM. First-line treatment in advanced colorectal cancer-New options in metastatic disease. Canc ChemoRev, 3:137-143, 2008.
18. Davies JM*, Goldberg RM, State of the Art: A Review of First-Line Therapeutic Strategies in Metastatic Colorectal Cancer, Oncology, 22:1470-1478, 2008.

E-mail: richard_m_goldberg@med.unc.edu
Telephone: 919-966-5720
FAX: 919-966-6735
Address: CB 7305, 170 Manning Dr Chapel Hill, NC 27599

Click here to update this profile